Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

Abstract Background Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We assessed the association between IR and cardio-renal outcomes and the effect...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	J. David Smeijer, Donald E. Kohan, Peter Rossing, Ricardo Correa-Rotter, Adrian Liew, Sydney C.W. Tang, Dick de Zeeuw, Ron T. Gansevoort, Wenjun Ju, Hiddo J. Lambers Heerspink
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2023-09-01
Rangatū:	Cardiovascular Diabetology
Ngā marau:	Insulin resistance Atrasentan Endothelin receptor antagonist Chronic kidney disease Type 2 diabetes
Urunga tuihono:	https://doi.org/10.1186/s12933-023-01964-8
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!